Melphalan is used as a "palliative" treatment to relieve symptoms of multiple myeloma (a type of blood cancer) or a certain type of ovarian cancer. Melphalan injection is used as a "conditioning ...

[2] HDM Melphalan intravenously: 200 mg /m 2 in 2 days intravenously IDM Melphalan intravenously: 100 - 140 mg /m 2 in 2 days intravenously HDex Dexamethasone orally: 40 mg on days 1 - 4 ...

Melphalan 200 mg/m 2 vs melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 115 , 1873–1879 (2010). Article CAS PubMed Google Scholar ...

O'Donnell and colleagues also emphasized that of the 45 patients who were evaluable for response after four cycles of treatment, just five proceeded to undergo high-dose melphalan (Alkeran ...

Melphalan is a chemotherapy agent, prescribed for multiple myeloma, melanoma, and ovarian carcinoma. The risk or severity of adverse effects can be increased when Melphalan is combined with ...

Review the side-effects of Melphalan as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

NICE is unable to make a recommendation about the use in the NHS of melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because ...

Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.

Recent evidence suggests that patients with newly diagnosed multiple myeloma treated with high-dose melphalan therapy prior to undergoing autologous stem cell transplantation (ASCT) are more ...

The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and ...

A retrospective comparative study of CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) and Selective Internal Radiation Therapy (SIRT) citing a statistically ...

NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence ...